- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05605301
Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy
This project studies how 2-deoxy-glucose (2DG) pills are absorbed and distributed in people with epilepsy. 2DG is similar to glucose, the main energy source for the brain, but it cannot be used as energy. During seizures, neurons are at a very high metabolic state with huge glucose metabolism as glycolysis is accelerated to supply the high metabolic needs of a seizure. 2DG is taken up by cells but cannot be metabolized by the first enzyme in the glycolytic pathway, thus is stops, or "clogs up", glycolysis. Since brain metabolism is almost entirely dependent on glucose as an energy source, glycolysis is arrested and may stop seizures. It is hoped that 2DG will stop seizures by interfering with the brain's energy use.
This is an open-label phase 2 study of the pharmacokinetics (PK), safety, and tolerability of 2DG administered orally to adult epilepsy patients. A 3-level 2DG dose escalation is planned in sequential cohorts of 3 subjects in each cohort with review of each cohort before proceeding to the next cohort. On the day of oral 2DG exposure, subjects will receive a single dose of 40 mg in the first cohort, a single dose of 60 mg in the second cohort, and two 60 mg doses (60 mg bid) in the third cohort.
After 3 subjects have completed dosing at Dose Level 1 (40 mg/day), the safety and PK results will be reviewed. The Study Committee will determine if the next cohort should be enrolled at Dose Level 2 (60 mg/day). The same procedure will be repeated to determine if the next cohort should be enrolled at Dose Level 3 (60 mg bid = 120 mg/day). If the Study Committee determines that the most recent dose is not tolerated or that there are significant adverse events, the subsequent Dose Level will not be enrolled.
A standard time-concentration curve will be constructed from the 2DG levels obtained from the PK blood draws. Parameters will be calculated for: time to maximum concentration (tmax), maximum concentration (Cmax), elimination rate, half-life (t1/2), AUC, and derived parameters. Statistical analysis will not be performed because of the small n, but this will nevertheless establish the PK profile of 2DG in people with epilepsy. The most important parameter will be the AUC which determines drug exposure.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Stacy R Thompson, BSN
- Phone Number: 4349824315
- Email: src2h@virginia.edu
Study Contact Backup
- Name: Rohit S Kuruvilla, MD
- Phone Number: 4342436281
- Email: rsk3dz@virginia.edu
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Confirmed diagnosis of epilepsy. For the purpose of inclusion, the seizure types include complex partial, simple partial motor, primary generalized tonic-clonic, secondary generalized tonic-clonic, tonic, clonic and atonic seizures, as well as simple partial and absence seizures.
- Stable treatment regimen with no change in antiepileptic drugs or antiepileptic drug doses for 28 days prior to enrollment.
- Women of childbearing potential must be using a standard method of birth control and agree not to become pregnant during the trial. Men must agree to not father a child during the trial.
- BMI must be between 18 and 35.
Exclusion Criteria:
- Occurrence of non-epileptic psychogenic spells within 2 years prior to enrollment.
- Current or past history of diabetes or any abnormality of glucose metabolism.
- Use of glucocorticoids, hypoglycemic agents (e.g. metformin) or any drug that alters glucose levels.
- Use of any drug that is expected to alter glucose absorption, metabolism or serum measurements.
- Clinically significant psychiatric or medical disease.
- Previous therapeutic use of 2DG.
- Pregnant or nursing women.
- Use of an investigational medication within 2 months prior to enrollment.
- Supine systolic blood pressure < 90 or > 160 mm Hg or diastolic > 90 mm Hg, or pulse < 60 or > 110 BPM.
- Clinically significant abnormal 12-lead ECG.
- Baseline prolongation of the QTc interval > 450 msec.
- Clinically significant abnormal result by speckle tracking echocardiography (STE).
- Elevated ALT or AST more than 1.5 times upper reference limit.
- Baseline fasting glucose < 60 or > 110.
- History of status epilepticus within 6 months prior to enrollment.
- Progressive structural brain lesion or illness likely to progress during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequential ascending dose cohort
Cohort 1 will receive single 40 mg dose once.
Cohort 2 will receive single 60 mg dose once.
Cohort 3 will receive (2) 60 mg dose on one occasion.
|
2DG will be formulated as an solid dosage form and administered orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics
Time Frame: Collected from time of drug administration to 24 hours post dose
|
AUC will be calculated from 2DG blood levels collected at time 0, 15, 30, 45, and 60 minutes and at 2, 4, 6, 12, and 24 hours after single dose of 2DG.
|
Collected from time of drug administration to 24 hours post dose
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: From time of drug administration until 24 hours post-dose
|
Spontaneously reported adverse events will be summarized by type and severity by the most recent version of MedRA terminology.
Adverse events will be graded as mild, moderate, or severe and by whether the relationship to study drug is related, possibly related, or unrelated.
|
From time of drug administration until 24 hours post-dose
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nathan B Fountain, MD, University of Virginia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSR210085
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy; Seizure
-
UMC UtrechtUnknownEpilepsy Intractable | Epileptic Seizure | Motor SeizureNetherlands
-
Michael A. Gelfand, MD, PhDEpilepsy FoundationCompletedGeneralized Tonic Clonic Seizure | Drug Resistant Epilepsy | Drop Seizures | Complex Partial Seizure | Fall Due to SeizureUnited States
-
Children's Hospital of Fudan UniversityRecruitingSeizures | Seizure Disorder | Seizure Newborn | Seizure GeneralizedChina
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedEpilepsy | Epilepsies, Partial | Partial Seizure Disorder | Complex Partial Seizure DisorderCosta Rica, Peru, El Salvador, Guatemala
-
Vitaflo International, LtdChildren's Hospital of PhiladelphiaCompletedSeizure DisordersUnited States
-
Dokuz Eylul UniversityRecruiting
-
University of California, San FranciscoCompleted
-
Brain SentinelUnknownEpilepsy | Non-Epileptic Seizure | Motor SeizureAustria
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedEpilepsy | Seizures | Partial Seizure DisorderUnited States, Australia, France, Belgium, Taiwan, Spain, Argentina, Poland, India, Ukraine, Finland, Korea, Republic of, Russian Federation, Chile, Thailand, Hungary, Israel, New Zealand, Canada, Mexico, Norway, Netherlands, South...
-
Reliev TechnologiesNot yet recruitingFocal Epilepsy | Epilepsy; Seizure
Clinical Trials on Oral 2-Deoxy-D-Glucose (2DG)
-
Threshold PharmaceuticalsCompletedBreast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Lung CancerUnited States
-
National Institute of Arthritis and Musculoskeletal...CompletedLupus Erythematosus | SystemicUnited States
-
Abramson Cancer Center of the University of PennsylvaniaTerminatedNon-Hodgkin LymphomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Institutes of Health (NIH)Terminated
-
CellSight Technologies, Inc.University of California, San FranciscoRecruiting
-
CellSight Technologies, Inc.National Institute of Allergy and Infectious Diseases (NIAID); University of...Recruiting
-
G.ST Antivirals GmbHCompletedAcute NasopharyngitisAustria
-
National Taiwan University HospitalCompleted
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Melanoma Research AllianceCompletedMelanoma | Non-small Cell Lung Cancer (NSCLC) | Renal Cell Carcinoma (RCC)United States
-
G.ST Antivirals GmbHRecruitingAcute NasopharyngitisNetherlands